DNASE1L3 rs35677470变异增加系统性硬化症患者肺动脉高压易感性与死亡风险
本研究在三个系统性硬化症(SSc)队列中分析DNASE1L3 R206C变异与死亡及肺部结局的关联。死亡分析纳入2366例患者,校正年龄和性别后该变异与死亡风险显著增加相关(HR 1.16, 95%CI 1.02-1.32);毛细血管前肺动脉高压分析纳入1170例患者,校正年龄、性别和ILD后该变异与毛细血管前肺动脉高压风险显著增加相关(HR 1.69, 95%CI 1.31-2.19)。结论提示DNASE1L3功能丧失与SSc患者肺动脉高压易感性相关。
要点
- DNASE1L3 R206C变异与SSc患者死亡风险增加相关(HR 1.16)。
- 该变异与毛细血管前肺动脉高压风险增加相关(HR 1.69)。
- 多数毛细血管前肺动脉高压患者无ILD,提示WHO第1组肺动脉高压。
核心结论
- DNASE1L3 R206C变异与SSc患者死亡风险及毛细血管前肺动脉高压风险增加显著相关。
研究设计与样本
- 在UTHealth Houston、Royal Free Hospital和Johns Hopkins University三个队列中 ascertain 死亡、肺动脉高压和间质性肺病。
- 死亡分析纳入2366例患者,其中46.6%已死亡;毛细血管前肺动脉高压分析纳入1170例患者,其中20.3%有毛细血管前肺动脉高压。
- 使用Cox比例风险模型估计死亡风险和自SSc发病起毛细血管前肺动脉高压的时间-事件风险,并进行Meta分析生成总体风险估计。
主要发现
- 校正SSc发病年龄和性别后,DNASE1L3 R206C与死亡风险显著增加相关(HR 1.16, 95%CI 1.02-1.32)。
- 校正SSc发病年龄、性别和ILD后,DNASE1L3 R206C与毛细血管前肺动脉高压风险显著增加相关(HR 1.69, 95%CI 1.31-2.19)。
- 多数毛细血管前肺动脉高压患者无ILD,提示为WHO第1组肺动脉高压(PAH)。
临床怎么用
- 对携带DNASE1L3 R206C变异的SSc患者应加强死亡风险评估和肺动脉高压监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: A loss-of-function variant in deoxyribonuclease 1-like 3 (DNASE1L3), encoding Arg to Cys substitution at amino acid 206 (R206C), was previously identified as a heritable susceptibility factor for systemic sclerosis (SSc). We analysed mortality and pulmonary outcomes in patients with SSc with or without the DNASE1L3 R206C variant. METHODS: Mortality, pulmonary hypertension (PH), and interstitial lung disease (ILD) were ascertained in the UTHealth Houston, Royal Free Hospital, and Johns Hopkins University cohorts. Mortality risk and precapillary PH time-to-event from SSc onset were estimated using Cox proportional hazards models. Meta-analyses were performed to generate overall risk estimates. RESULTS: In the mortality analysis (n = 2366 patients, 46.6% of whom were deceased), after adjustment for age of SSc onset and sex, DNASE1L3 R206C was associated with significantly greater mortality (hazard ratio [HR]: 1.16, 95% CI: 1.02-1.32). In the precapillary PH analysis (n = 1170 patients, 20.3% of whom had precapillary PH), after adjustment for age of SSc onset, sex, and the presence of ILD, DNASE1L3 R206C was associated with significantly greater precapillary PH risk (HR: 1.69, 95% CI: 1.31-2.19). The majority of patients with precapillary PH did not have ILD, indicating that they had WHO Group I, ie pulmonary arterial hypertension (PAH). CONCLUSIONS: We report a previously unknown impact of DNASE1L3 polymorphism on PAH susceptibility in SSc. The association between loss-of-function of an immunoregulatory gene (DNASE1L3) and PAH susceptibility supports further exploration of downstream sequelae of DNASE1L3 dysfunction in SSc pathogenesis and the mechanisms underlying the well-recognised but poorly understood susceptibility of patients with SSc to PAH.
引用
- Skaug B, Rodolfi S, Denton CP, et al. Pulmonary arterial hypertension susceptibility and mortality among patients with systemic sclerosis with the DNASE1L3 rs35677470 (Arg206Cys) variant. Ann Rheum Dis. 2026. PMID: 42248770. doi:10.1016/j.ard.2026.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。